Pharmaceutical composition of nanoparticles
View Patent ↗The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
1. A composition of nanoparticles, said nanoparticles comprising a shell portion that is dominated by positively charged chitosan, and a core portion that consists of said positively charged chitosan, one negatively charged substrate, surfactants, and optionally a zero-charge compound or a bioactive agent.
2. The composition according to claim 1 , wherein said chitosan is N-trimethyl chitosan, EDTA-chitosan, low molecular weight chitosan, pegylated chitosan (PEG-chitosan), mono-N-carboxymethyl chitosan, N-palmitoyl chitosan (NPCS), chitosan derivatives, or combinations thereof.
3. The composition according to claim 1 , wherein said negatively charged substrate is PGA-complexone conjugate, γ-PGA, α-PGA, derivatives of PGA, or salts of PGA.
4. The composition according to claim 1 , wherein said nanoparticles are freeze-dried, thereby said nanoparticles being in a powder form.
5. The composition according to claim 1 , wherein said nanoparticles are mixed with a cryoprotectant and then freeze-dried, thereby said nanoparticles being in a powder form.
6. The composition according to claim 5 , wherein said cryoprotectant is selected from the group consisting of trehalose, hexan-1,2,3,4,5,6-hexyl, mannitol, dimethyl sulfoxide, ethylene glycol, glycol, 2-methyl-2,4-pentanediol, propylene, sucrose, and combinations thereof.
7. The composition according to claim 1 , wherein said nanoparticles are encapsulated in a capsule.
8. The composition according to claim 7 , wherein said capsule is made of methyl cellulose selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), carboxymethyl cellulose, hydroxyethyl methyl cellulose (HEMC), and methyl cellulose derivatives.
9. The composition according to claim 7 , wherein said capsule is treated with an enteric coating.
10. The composition according to claim 7 , wherein said capsule further comprises a pharmaceutically acceptable carrier, diluent, excipient, desiccant, solubilizer, bubbling agent, or emulsifier.
11. The composition according to claim 10 , wherein said surfactants are in particulate form or configuration.
12. The composition according to claim 7 , wherein said capsule is made of gelatin.
13. The composition according to claim 1 , wherein said nanoparticles are treated with an enteric coating.
14. The composition according to claim 1 , wherein said zero-charge compound is an absorption enhancer.
15. The composition according to claim 1 , wherein said bioactive agent is an anti-diabetic compound.
16. The composition according to claim 15 , wherein said anti-diabetic compound is selected from the group consisting of insulin, an insulin analog, GLP-1, a GLP-1 analog, an insulin sensitizer, an insulin secretagogue, an inhibitor of dipeptidyl peptidase 4, metformin, alpha-glucosidase inhibitors, amylin analog, sodium-glucose co-transporter type 2 (SGLT2) inhibitors, benfluorex, tolrestat, mitofusin 1, mitofusin 2, bacillus Calmette-Guerin (BCG), vesicle-associated membrane protein 8 (VAMP8), and combinations thereof.
17. The composition according to claim 1 , wherein said nanoparticles are administered via an oral route.
18. The composition according to claim 1 , wherein said surfactants are coated on the nanoparticles.
19. The composition according to claim 1 , wherein said bioactive agent is selected from the group consisting of an anti-epileptic drug, anti-inflammatory drug, meningitis antagonist, and anti-oxidant, wherein said anti-inflammatory drug is selected from the group consisting of mesalazine, prednisone, a TNF inhibitor, azathioprine (Imuran), methotrexate, 6-mercaptopurine, nystatin, antifungal agent, itraconazole, and fluconazole.
20. The composition according to claim 1 , wherein said bioactive agent is selected from the group consisting of an antagonist for treatment of multiple sclerosis, neuromyelitis optica, late-stage neurological trypanosomiasis, progressive multifocal leukoencephalopathy, HIV encephalitis, and Alzheimer's diseases.